Click image to enlarge
The Phospho(Tyr1349)/Total Met Whole Cell Lysate Kit provides assay-specific components for the quantitative determination of phospho-Met (Tyr1349) and total Met in human whole cell lysates.
Please note: MSD has transitioned this product to a status of “made-to-order” with a minimum order size of 25 plates. For an order of the 5-plate pack size, the minimum quantity is 5 packs (25 plates). The 1-plate and 20-plate pack sizes have been discontinued.
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Phosphoproteins
,
Intracellular Signaling
|
|
|
Analyte(s)
|
|
Met
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO SECTOR S 600MM
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex SQ 120
,
MESO SECTOR S 600
|
|
|
Plate Type
|
|
96-well
|
|
|
Capture Antibody
|
|
Phospho-Met: Rabbit Polyclonal
Total Met: Goat Polyclonal
|
|
|
Detection Antibody
|
|
Phospho-Met: Rabbit Polyclonal
Total Met: Goat Polyclonal
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Kit Model
|
|
Whole Cell Lysate
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Phosphatase Inhibitor I 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Phosphatase Inhibitor II 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Protease Inhibitor Solution 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
SULFO-TAG Anti-Total MET Antibody
|
2-8 °C
|
1 vial
(375 μL)
|
|
|
|
Phospho/Total Met Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
1 bottle
(200 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(15 g)
|
|
|
|
|
≤-10 °C
|
1 vial
(0.2 mL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
|
|
|
|
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
|
|
|
|
S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab.
|
|
|
|
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody Onartuzumab.
|
|
|
|
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters